Literature DB >> 18301302

Thrombopoietin is a growth factor for rat hepatic progenitors.

Eva Schmelzer1, Andrea Deiwick, Helge Bruns, Henning C Fiegel, Augustinus Bader.   

Abstract

OBJECTIVE: The liver is the primary site of hematopoiesis during fetal development; it has been shown that thrombopoietin (TPO) produced by the liver during fetal development is a major regulator of megakaryocytopoiesis. As maximum liver growth and hematopoiesis occur simultaneously, we hypothesized that TPO may act as a growth factor for hepatic progenitors. Therefore, the influence of TPO on the proliferation of fetal hepatic progenitors in vitro compared with that of adult hepatocytes was analyzed. The expression of the TPO receptor, c-mpl, was investigated in fetal and adult liver.
METHODS: Cell proliferation was measured by bromodeoxyuridine incorporation and total cell counts. TPO and c-mpl gene expression was investigated by reverse transcription polymerase chain reaction. The cell surface expression of c-mpl was analyzed in fetal and adult human liver by immunohistochemistry.
RESULTS: Hepatic progenitors of fetal and adult liver but not hepatocytes expressed the TPO receptor, c-mpl, on the cell surface. Fetal hepatic progenitors expressed mRNA for TPO and its receptor. TPO stimulated cell proliferation and increased cell numbers of cultured rat fetal hepatic progenitors but not adult hepatocytes.
CONCLUSION: We conclude that TPO acts in addition to its known role in megakaryocytopoiesis as a growth factor for hepatic progenitors but not hepatocytes in vitro; thus, TPO represents a growth factor for hepatic progenitors during fetal liver development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301302     DOI: 10.1097/MEG.0b013e3282f246e6

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Limited therapeutic efficacy of thrombopoietin on the regeneration of steatotic livers.

Authors:  Kerstin Abshagen; Franziska Mertens; Christian Eipel; Brigitte Vollmar
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

2.  Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction.

Authors:  Stefanie Haegele; Florian Offensperger; David Pereyra; Elisabeth Lahner; Alice Assinger; Edith Fleischmann; Birgit Gruenberger; Thomas Gruenberger; Christine Brostjan; Patrick Starlinger
Journal:  PLoS One       Date:  2015-01-22       Impact factor: 3.240

3.  The Eltrombopag antitumor effect on hepatocellular carcinoma.

Authors:  Tomohiro Kurokawa; Soichiro Murata; Yun-Wen Zheng; Kenichi Iwasaki; Keisuke Kohno; Kiyoshi Fukunaga; Nobuhiro Ohkohchi
Journal:  Int J Oncol       Date:  2015-09-23       Impact factor: 5.650

Review 4.  Moving towards in situ tracheal regeneration: the bionic tissue engineered transplantation approach.

Authors:  Augustinus Bader; Paolo Macchiarini
Journal:  J Cell Mol Med       Date:  2010-04-19       Impact factor: 5.310

5.  Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma.

Authors:  Barbara Vizio; Ornella Bosco; Ezio David; Gian Paolo Caviglia; Maria Lorena Abate; Martina Schiavello; Angela Pucci; Antonina Smedile; Gianluca Paraluppi; Renato Romagnoli; Enrico Lupia; Graziella Bellone; Giuseppe Montrucchio
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

Review 6.  Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy.

Authors:  Arbi Aghali
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 7.  Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases.

Authors:  Enrico Lupia; Alberto Goffi; Ornella Bosco; Giuseppe Montrucchio
Journal:  Mediators Inflamm       Date:  2012-04-05       Impact factor: 4.711

8.  Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases.

Authors:  Takumi Kawaguchi; Masahito Nakano; Manabu Satani; Shuji Sumie; Shingo Yamada; Keisuke Amano; Ryoko Kuromatsu; Michio Sata
Journal:  Oncol Lett       Date:  2014-03-14       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.